India advances indigenous HPV screening kits for cervical cancer through DBT-BIRAC partnership
Department of Biotechnology-led initiative under review; Minister Jitendra Singh highlights public-private collaboration and…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
New England Journal of Medicine
Race for approval of first oral GLP-1R drug in obesity intensifies with four in phase III trials:…
Oral GLP-1 receptor drugs emerge as the next frontier in obesity treatment, with key players racing for first approval amidst…
Promising MND drug helps slow disease progression and benefits patients physically
Patients on the trial reported better patient mobility and lung function after 12 months
US FDA approves Mallinckrodt’s Terlivaz for injection to treat Hepatorenal Syndrome
Terlivaz is the first and only FDA-approved treatment for adults with HRS involving rapid reduction in kidney function
Dapagliflozin reduces cardiovascular death risk in patients with preserved ejection fraction
Results were presented at European Society of Cardiology Congress 2022, and published in 'New England Journal of Medicine'
ZeNix trial shows effectiveness of BPaL regimen for TB can be maintained with reduced dosing of…
The results from the trial, which was led by TB Alliance, were published in the 'New England Journal of Medicine'
Cancer disappears from every patient’s body in drug trial in US: Report
Besides their tumours disappearing completely, none of the participants reported any severe side-effects either, says the research…
Rilzabrutinib shows promise in phase-I/II clinical trial for blood disorder
The findings, published in the 'New England Journal of Medicine,' has shown that cells called macrophages are primarily…
CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated…
The recommendation is based on pivotal data from the phase-III Polarix study
Novavax files for Conditional Marketing Authorisation of COVID-19 vaccine in Switzerland
The submission for the regulatory evaluation of the vaccine includes data from two phase-III clinical trials